ABSTRACT-We examined the effects on urine outflow rate after microinjections of thiorphan (a carboxy peptidase inhibitor) and bestatin (an aminopeptidase inhibitor) into the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei of anesthetized hydrated rats to determine the possible role of neuro peptides in the regulation of urine production. After individual microinjection of the peptidase inhibitors into the nuclei, only thiorphan at 100 nmol administered into the PVN significantly decreased the urine outflow rate. Two consecutive microinjections of the peptidase inhibitors at 100 nmol each into the nuclei induced potent antidiuresis. These effects after microinjections of the peptidase inhibitors into the PVN and SON were diminished by pretreatment with [Sarl,Ile8]angiotensin (ANG) II (an ANG II receptor antago nist) and naloxone (an opioid receptor antagonist) in the PVN and with [Sarl,Ile8]ANG II in the SON, respectively. A vasopressin (AVP) receptor antagonist, d(CH2)5-D-Tyr(Et) VAVP (i.v.), completely blocked the antidiuresis by microinjections of the peptidase inhibitors into both the nuclei. Urinary osmotic pressure was significantly increased by consecutive microinjections of the peptidase inhibitors into the PVN and SON. These results suggest that endogenously-released ANG II and opioid peptides in the PVN and ANG II in the SON regulate urine production mediated through increased AVP release.
The hypothalamus contains many kinds of neuro peptides such as enkephalins, endorphins, corticotropin releasing factor, tachykinins and angiotensin II (ANG II) (1, 2). Immunohistochemical studies have demonstrated the presence of peptide-containing nerve terminals and fibers in the hypothalamus (1, 3, 4) . The neuropeptides in the hypothalamus, as well as adrenoceptors (5 9) and cholinoceptor (10, 11) agonists, play a role in regulating vasopressin (AVP) secretion from the neurohypophysis. Bradykinin, cholecystokinins, substance P, neuro peptide Y, opioid peptides and ANG II applied into the hypothalamus increase AVP release into the circulation (1, 9, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . ANG II is probably the most potent AVP releasing agent among the adrenoceptor and cholinoceptor agonists and neuropeptides as indicated by their relative effective doses. The mechanism for the ANG II-induced effect is increased release of norepinephrine (9, 12, 21) .
Endogenously-released neuropeptides are degraded by aminopeptidases and/or carboxypeptidases, and then their effects disappear. Therefore, aminopeptidase and carboxypeptidase inhibitors are useful tools for inves tigating the in vivo roles of the neuropeptides. Effects of carboxypeptidase and/or aminopeptidase inhibitors applied into the central nervous system are reported to produce antinociceptive effects mediated through opioid receptors (22, 23) . Moreover, the inhibitors block break down of the other neuropeptides, ANG II, tachykinins and so on (22 27) .
The purpose of the present study is to determine the role of endogenously-released neuropeptides of the paraventricular (PVN) and supraoptic (SON) nuclei in the regulation of urine production. We examined the effects of thiorphan (a carboxypeptidase inhibitor) and bestatin (an aminopeptidase inhibitor), when microinjected directly into the PVN and SON, on the urine outflow rate and the mechanisms responsible for the effect on the urine outflow rate. #deceased 
MATERIALS AND METHODS

Animals
A total of 118 male Wistar rats (290-370 g, 9 to 11 week-old; Kitayama Labes Co., Ina) were used. The rats were housed at 22± 1 C with a 12-hr light-dark cycle. They were fasted approximately 17 hr before the experiments were started, but had access to water ad libitum.
Surgical procedure
The rats, starved overnight, were loaded with tap water (5 ml/100 g body weight) and 45 min later, were anesthe tized with the same volume of 12% ethanol, using stomach intubation. The rats were cannulated with poly ethylene tubes into the urinary bladder, the trachea and the jugular vein. In some animals, an additional poly ethylene cannula filled with heparinized saline was insert ed into the carotid artery. Then, they were immobilized in a stereotaxic apparatus (Takahashi Co., Tokyo) and were implanted with a stainless steel cannula (outer diameter: 200 pm) into the right SON (coordinates: 6.3 mm anterior to the lambda, 1.3 mm lateral to the midline, 9.0 mm from the dura) or the right PVN (5.6 mm, 0.3 mm, 8.0 mm) according to the atlas of Konig and Klippel (28) .
Measurement of urine outflow rate Locke's solution containing 3% ethanol was continu ously infused at a rate of 0.1 ml/min into the jugular vein cannula during the experiments in order to maintain anesthesia and a measurable constant level of urine out flow rate. Urinary drops flowing from the bladder can nula were counted by a photoelectric drop counter (DCT 102; Unique Medical, Inc., Tokyo) every 10 min. The volume of one urinary drop was 20 p1. Urine outflow was presented as the percentage of the control outflow (num ber of urinary drops for a 10-min period immediately preceding drug administration).
The urine outflow rate became constant at approximately 1 hr after all surgical procedures had finished, and the constant rate was kept for 5-6 hr (29). One animal was not injected more than twice. The experiments were performed with a urine out flow rate of 40-200 pl/min.
Administration of drugs
After the urine outflow rate was constant for at least 20 min, drugs were injected into the nucleus or intravenous ly.
Microinjection of drugs into the nuclei: A drug solu tion (1 pl) was microinjected into the PVN or SON using a microsyringe connected to the stainless steel cannula inserted into the nucleus. The following drugs were em ployed: peptidase inhibitors (thiorphan: 30 or 100 nmol in 0.3% NaCI containing 0.1 N NaOH, bestatin: 30 or 100 nmol in saline), an opioid antagonist (naloxone: 600 nmol in saline), and an ANG II antagonist ([Sarl, Ile8] ANG II: 0.1 or 1 nmol in saline). Microinjections were carried out at a rate of 0.3 p1/min. In the case of con secutive microinjections of the peptidase inhibitors, thiorphan (1 pl) followed by bestatin (1 pl) were microin jected into the nucleus with the same procedure. To in vestigate the influence of the antagonists on the anti diuretic effects induced by consecutive microinjections of the two peptidase inhibitors at 100 nmol each into the nucleus, the nucleus was pretreated with the antagonist at 60 (intra-PVN injection) or 50 (intra-SON injection) min for naloxone and at 30 min for [Sarl, Ile8] ANG II before consecutive microinjections of the peptidase inhibitors into the same nucleus.
Intravenous injection of drugs: AVP (4 mU in 0.1 ml saline) and an AVP antagonist, d(CH2)5-D-Tyr(Et)VAVP, (50 pg/kg in 0.1 ml saline) were injected intravenously through the jugular vein cannula. In order to examine whether or not increased AVP release was involved in antidiuresis induced by consecutive microinjections of the peptidase inhibitors at 100 nmol each into the nuclei, in travenous injection of the AVP antagonist was performed at 40 min before consecutive microinjections of the pepti dase inhibitors into the nuclei.
Measurement of urinary osmotic pressure
Urine flowing from the urinary bladder cannula was collected for 10 min in test tubes to measure urinary os motic pressure after consecutive microinjections of the two peptidase inhibitors (100 nmol each) into the nuclei and after i.v. injection of AVP. Urinary osmotic pressure was measured at 0 min as the control level, at 40 min after the intra-PVN injection or 30 min after intra-SON injec tion and i.v. injection as the peak response, and at 80 min after administration as the recovered level, using the freezing point depression method (Fiske Osmometer, Model G-62; Fiske Associates, Inc., Uxbridge, MA, USA).
Measurement of visceral functions
In some experiments, visceral functions were simul taneously monitored with the urine outflow rate. Blood pressure of the carotid artery was measured through a pressure transducer (MPU-0.5-290-III; Nihon Kohden Kogyo, Co., Tokyo). Thermister probes (SR-115S and MGA 111-219, Nihon Kohden Kogyo, Co.) in the trachea cannula and the rectum were used to measure respiratory rate and rectal temperature, respectively. Measurement of heart rate was by cardiography (FD-13; Fukuda, Tokyo).
Drugs
The following drugs were used: thiorphan (Peninsula Laboratories, Inc., Belmont, CA, USA), bestatin hydrochloride,
(a gift from Prof. K.G. Hofbauer, Cardiovascular Division, Ciba-Geigy, Ltd., Basel, Switzerland) and naloxone hydrochloride (a gift from Sankyo Co., Tokyo). The other chemicals used were of the highest grade available.
Histological procedure
After the experiments, the injection sites were histolog ically verified by microinjection of methylene blue. Sites stained by methylene blue were confirmed under a micro scope after the brain was cut into 15-pm coronal sections with a microtome ( 
RESULTS
Effects of bestatin and thiorphan on urine outflow rate Figure 1 shows some examples of identified microinjec tion sites for the drugs into the PVN and SON.
As shown in Fig. 2A , microinjection of thiorphan at 100 nmol into the PVN elicited weak but significant decreases in the urine outflow rate at 20 and 30 min after injection, compared with the urine outflow rate after ad ministration of vehicle at the corresponding time points.
After injection of bestatin at 100 nmol into the PVN, the urine outflow rate showed a decreasing tendency at 20-40 min after injection; however, this was not significant (Fig.   2) . Microinjection of the two peptidase inhibitors into the SON did not change the urine outflow rate (Fig. 2) . •: 100 nmol thiorphan+ 100 nmol bestatin, A: 30 nmol thiorphan+30 nmol bestatin, LI: vehicle. At the 0-min time points, thiorphan followed by bestatin was microinjected into the nuclei. Values represent the mean±S.E.M. of 4-9 experiments. *P <0 .05 vs the vehicle-injected group (LI) at the corresponding time points (one-way ANOVA followed by Fisher's PLSD test).
On the other hand, consecutive microinjections of the two peptidase inhibitors at 100 nmol each into the nuclei produced potent antidiuretic effects (Fig. 3) . The time course of the antidiuresis was relatively slow with 10-min latency, the peak response at 30 min after administration and 80-min duration. Consecutive microinjections of the peptidase inhibitors at a lower dose of 30 nmol each into the nuclei showed no effects on the urine outflow rate (Fig. 3) . Consecutive microinjections of one peptidase inhibitor at 30 nmol and another at 100 nmol into the SON tended to decrease the urine outflow rate, but not significantly (30 nmol thiorphan and 100 nmol bestatin: 76±20%, n=3; 100 nmol thiorphan and 30 nmol besta tin: 70± 17010 of the control level at 30 min after adminis tration, n = 5). Also, thiorphan and bestatin at 100 nmol each, when consecutively microinjected into sites 1 mm above the SON and 1 mm toward the midline to the SON, did not show any significant decrease in the urine outflow rate (1 mm above the SON: 115 ± 8%, n = 5; 1 mm toward the midline to the SON: 89±6% of the control level at 30 min after administration, n=3). The urine outflow rate was not significantly changed after microinjections of saline, 0.3% NaCI containing 0.1 N NaOH and both the vehicles into the PVN and SON (Figs. 2 and 3 ).
Blood pressure, heart rate, respiratory rate and rectal temperature were not significantly changed by consecu tive microinjections of the peptidase inhibitors into the SON (Table 1) . However, after consecutive injections of the peptidase inhibitors into the PVN, heart rate, respira tory rate and rectal temperature were elevated during the following time periods after the administration (injection at O min): 40-80 min, 30-80 min and 50-80 min, respectively (Table 1) . These increases were still observed when the decreases in the urine outflow rate returned to the control rate (Fig. 3) . Consecutive microinjections of the peptidase inhibitors into the PVN did not induce any effects on blood pressure. There were no significant changes in all functions after consecutive microinjections of vehicles (0.3% NaCI containing 0.1 N NaOH followed by saline) into the nuclei (Table 1) . (Figs. 4 and 5) . Microinjection of naloxone alone into the SON showed no statistically significant decrease in the urine outflow rate; however, microinjection into the PVN elicited the transient antidiuretic effects. Naloxone inhibited the anti diuretic effects of the peptidase inhibitors microinjected into the PVN, but not those microinjected into the SON. The inhibitory effect in the PVN was partial and a weak antidiuretic effect remained.
On the other hand, microinjection of [Sar',Ile8]ANG II alone into the nuclei did not have any effects on the urine outflow rate. The antidiuresis in both the nuclei were partially antagonized by only the higher dose of the an tagonist. Figure 6A shows significant increases in uri nary osmotic pressure after consecutive microinjections of the peptidase inhibitors into the PVN and SON. These increases in urinary osmotic pressure were similar in ex tent to that after intravenous injection of 4 mU AVP. Also, no significant differences in the urine outflow rate were found among the three groups. The urinary osmotic pressure returned to the control level in all experiments when the urine outflow rate regained the control level. Consecutive microinjections into the nuclei and intra venous injection of the vehicles did not significantly alter the urine outflow rate and urinary osmotic pressure (Fig. 6B) .
The 
DISCUSSION
A number of studies have demonstrated that a car boxypeptidase inhibitor, thiorphan and bestatin, an aminopeptidase inhibitor, potentiate antinociceptive effects of opioid peptides (22, 23, 31) . Moreover, the peptidase inhibitors can produce antinociception by themselves (22, 23). The peptidase inhibitor-induced antinociception is antagonized by opioid antagonists, suggesting that these effects were produced by inhibiting the degradation of endogenously-released opioid peptides after administration of the peptidase inhibitors. In the present study, we showed that consecutive microinjec tions of the peptidase inhibitors into the PVN induced antidiuretic effects that were diminished by pretreatment with naloxone in the nucleus. Therefore, it is suggested that antidiuresis induced by consecutive microinjections of the peptidase inhibitors into the PVN involves an in crease in the opioid peptide concentration in the nucleus by administration of the peptidase inhibitors in the nucleus. This strongly supports the idea that endogenous opioid peptides in the PVN play a role in regulating urine production. The subtype of opioid receptors involved in the regulation is probably the o or i-subtype, because the dose of naloxone used in this study was relatively high. Naloxone is reported to have slightly higher affinity to the p-subtype than the other opioid receptor subtypes. A tenfold higher dose of naloxone is needed to block the o or K-subtype, compared to the dose blocking the , subtype (32). Our earlier studies under the same ex perimental conditions have demonstrated that D-Ala2 D-Leu5-enkephalin (a o-agonist) and dynorphin (a K agonist) applied into the PVN increase the plasma AVP level and result in antidiuresis that was partially inhibited by the dose of naloxone used in this study (19, 20) (19, 20, 33, 37) . Therefore, it is speculated that opioid mechanisms in the SON may have a role in the regulation under specific conditions. Thiorphan and bestatin also block degradation of ANG II (23 25), which is well-known to produce potent antidiuresis through increased AVP secretion in the cen tral nervous system (9, 12, 18, 21) . The inhibitory effect of the ANG II antagonist [Sarl, Ile8] ANG II on the antidi uresis provides evidence that ANG II receptors in both nuclei contribute to the regulation of urine production. Our previous report using the same experimental methods showed that potent antidiuresis of ANG II at 1 nmol microinjected into the nuclei was completely blocked by pretreatment with 1 nmol of the antagonist into the same nuclei (21). On the other hand, thiorphan and bestatin suppress degradation of the other peptides such as tachykinins, cholecystokinin and bradykinin (22) (23) (24) (25) (26) (27) . Therefore, involvement of these peptides can not be completely excluded in the antidiuresis. These peptides are reported to increase secretion of AVP (1, 13-15). Also, it has been demonstrated that thiorphan decreases cleavage of atrial natriuretic factor (38-41). However, this peptide suppresses the secretion of AVP (42).
To examine the possibility that the antidiuretic effect was produced by the peptidase inhibitors diffused outside the nuclei, the drugs were consecutively microinjected into the two sites at 1 mm from the SON. The urine out flow rate was not significantly changed by the peptidase inhibitors applied into these sites. The sites 1 mm above the SON and 1 mm toward the midline to the SON are also near the PVN, and lie at a distance of 1.2 mm di agonally anterior and 1.2 mm diagonally ventral to the PVN, respectively. Moreover, we have already showed that microinjection of norepinephrine and oxotremorine into the sites outside the nuclei do not influence the urine outflow rate (6, 7, 43) . Taken together, the peptidase inhibitor-induced antidiuresis probably resulted from increased concentration of the peptides in the nuclei by microinjection of the drugs into the nuclei.
Consecutive microinjections of bestatin and thiorphan into the nuclei produced antidiuresis through increased secretion of AVP, because intravenous injection of the AVP antagonist, d(CH2)5-D-Tyr(Et)VAVP, definitely blocked the effects. Also, increases in urinary osmotic pressure after microinjection of the peptidase inhibitors into the nuclei were similar to those after intravenous injection of AVP. It was previously reported that anti diuretic effects of ANG II, substance P, Met-enkephalin (a o-agonist), D-Ala2-Met5-enkephalinamide (a p and 5 agonist) and dynorphin (a K-agonist) microinjected into the SON and/or PVN resulted from AVP secretion (14, 15, 19, 20) . Under the ethanol-anesthetized water-loaded condition in this study, the basal secretion of AVP is suppressed (20) , and the urine outflow rate seems to increase compared with that under the conscious non hydrated condition. However, anesthetized hydrated rats can still produce diuretic effects after central injection of timolol, prostaglandins E2 and F2a (44 46) .
We measured blood pressure, heart rate, respiratory rate and rectal temperature as the factors that might be responsible for change in the urine outflow rate. These indexes, except for blood pressure, increased after microinjection of the peptidase inhibitors into only the PVN. The PVN seems to contribute to visceral functions more than the SON. The increases were significant from 30 min for respiratory rate, 40 min for heart rate and 50 min for rectal temperature after the administration and continued after the decrease in the urine outflow rate recovered to the control level. The findings showed that the antidiuretic effects did not result from these changes.
Individual microinjection of bestatin and thiorphan into the SON and that of bestatin into the PVN did not show any significant antidiuresis, however, consecutive microinjections of both the inhibitors into the nuclei produced powerful effects. This is the same phenomenon as the inhibitor-induced antinociception (22). Both inhi bition of aminopeptidase and carboxypeptidase is needed to obtain significant effects. For peptides of small molecular weight like enkephalins and ANG II, both the C and N-terminals seem to be important for the inter action with the receptors and then produce the effects.
The antidiuretic effects after individual and consecutive microinjections of the peptidase inhibitors into the PVN appeared to be slightly more marked than those in the SON. The most likely explanation for this phenomenon is that peptides, whose degradation is inhibited by thior phan and bestatin, regulate AVP release in the PVN more powerfully than in the SON. In our previous study, the effects of ANG II applied in the PVN were more marked than that in the SON (21). There remains a possibility that the activities of peptidases in the SON may be more potent than those in the PVN. No reports to date have presented measurements of peptidase activities in the SON and PVN.
In conclusion, consecutive microinjections of thior phan and bestatin into the SON and PVN decrease urine production through increased secretion of AVP, which is regulated by endogenously-released ANG II and opioid peptides in the PVN and ANG II in the SON. However, other mechanisms may be involved in the antidiuretic effects. The regulation of urine production by the pep tides in the PVN may be more marked than that in the SON.
